NCT03224325View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

September 9, 2018

Study Completion Date

September 9, 2018

Conditions
Healthy
Interventions
DRUG

TAK-831 Tablet T2

Tak-831 tablets.

DRUG

Placebo

TAK-831 placebo-matching suspension.

DRUG

TAK-831 Suspension

TAK-831 Suspension.

Trial Locations (1)

91206

California Clinical Trials Medical Group/PAREXEL, Glendale

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY